Keros Therapeutics (KROS) EBIAT (2019 - 2025)
Historic EBIAT for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$7.3 million.
- Keros Therapeutics' EBIAT rose 8625.27% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 13549.54%. This contributed to the annual value of -$187.4 million for FY2024, which is 2245.93% down from last year.
- Latest data reveals that Keros Therapeutics reported EBIAT of -$7.3 million as of Q3 2025, which was up 8625.27% from -$30.7 million recorded in Q2 2025.
- Keros Therapeutics' 5-year EBIAT high stood at $148.5 million for Q1 2025, and its period low was -$53.0 million during Q3 2024.
- For the 5-year period, Keros Therapeutics' EBIAT averaged around -$20.7 million, with its median value being -$29.7 million (2022).
- As far as peak fluctuations go, Keros Therapeutics' EBIAT tumbled by 32821.33% in 2022, and later skyrocketed by 44432.2% in 2025.
- Over the past 5 years, Keros Therapeutics' EBIAT (Quarter) stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then plummeted by 35.42% to -$40.2 million in 2023, then dropped by 14.37% to -$46.0 million in 2024, then soared by 84.18% to -$7.3 million in 2025.
- Its EBIAT stands at -$7.3 million for Q3 2025, versus -$30.7 million for Q2 2025 and $148.5 million for Q1 2025.